NZ622710A - Neuroendocrine tumor treatment using mtor inhibitors - Google Patents

Neuroendocrine tumor treatment using mtor inhibitors

Info

Publication number
NZ622710A
NZ622710A NZ622710A NZ62271006A NZ622710A NZ 622710 A NZ622710 A NZ 622710A NZ 622710 A NZ622710 A NZ 622710A NZ 62271006 A NZ62271006 A NZ 62271006A NZ 622710 A NZ622710 A NZ 622710A
Authority
NZ
New Zealand
Prior art keywords
mtor inhibitors
tumor treatment
neuroendocrine tumor
rapamycin
hydroxyethyl
Prior art date
Application number
NZ622710A
Inventor
Peter Wayne Marks
David Lebwohl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0523658A external-priority patent/GB0523658D0/en
Priority claimed from GB0601082A external-priority patent/GB0601082D0/en
Priority claimed from GB0602747A external-priority patent/GB0602747D0/en
Priority claimed from GB0607942A external-priority patent/GB0607942D0/en
Priority claimed from GB0609272A external-priority patent/GB0609272D0/en
Priority claimed from GB0609912A external-priority patent/GB0609912D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from NZ604127A external-priority patent/NZ604127A/en
Publication of NZ622710A publication Critical patent/NZ622710A/en

Links

Landscapes

  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is the use of 40-O-(2-hydroxyethyl)-rapamycin in the manufacture of a medicament for treating carcinoid tumours of the gastrointestinal tract. Also disclosed is the use of 40-O-(2-hydroxyethyl)-rapamycin in the manufacture of a medicament for treating invasiveness of carcinoid tumours of the gastrointestinal tract.
NZ622710A 2005-11-21 2006-11-20 Neuroendocrine tumor treatment using mtor inhibitors NZ622710A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0523658A GB0523658D0 (en) 2005-11-21 2005-11-21 Organic compounds
GB0601082A GB0601082D0 (en) 2006-01-19 2006-01-19 Organic Compounds
GB0602747A GB0602747D0 (en) 2006-02-10 2006-02-10 Organic compounds
GB0607942A GB0607942D0 (en) 2006-04-21 2006-04-21 Organic compounds
GB0609272A GB0609272D0 (en) 2006-05-10 2006-05-10 Organic compounds
GB0609912A GB0609912D0 (en) 2006-05-18 2006-05-18 Organic compounds
EP06120660 2006-09-14
NZ604127A NZ604127A (en) 2005-11-21 2006-11-20 Neuroendocrine tumor treatment using mtor inhibitors

Publications (1)

Publication Number Publication Date
NZ622710A true NZ622710A (en) 2015-08-28

Family

ID=54014420

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ622710A NZ622710A (en) 2005-11-21 2006-11-20 Neuroendocrine tumor treatment using mtor inhibitors

Country Status (1)

Country Link
NZ (1) NZ622710A (en)

Similar Documents

Publication Publication Date Title
IL191475A (en) Use of 40-o-(2-hydroxyethyl)-rapamycin for the manufacture of a medicament for the treatment of pancreatic neuroendocrine tumors
MX2009006779A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors.
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MY148491A (en) FUSED BICYCLIC mTOR INHIBITORS
EP2046973A4 (en) For the identification, assessment, and treatment of patients with cancer therapy
HK1140141A1 (en) Combination therapies comprising a quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TW200738725A (en) Unsaturated mTOR inhibitors
EP2759302A3 (en) 4F-benzoyl-TN14003 combined with rituximab for use in the treatment of a tumour
EP1720576A4 (en) Photodynamic therapy for the treatment of acne
HK1120441A1 (en) Drugs for treatment of ovarian cancer
EP3208615A3 (en) Uses of labeled hsp90 inhibitors
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
DE602004027824D1 (en) ANTITUMORAL AGENT WITH A HISTON DEACETYLASE INHIBITOR AND A TOPOISOMERASE II HEMMER
MX2013010770A (en) Treatment of solid tumours.
NZ592825A (en) A triazolothiadiazole inhibitor of c-met protein kinase
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
TW200633700A (en) Methods of using temozolomide formulation intrathecally in the treatment of cancers
MX2013006362A (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2007130501A3 (en) Combination therapy for treatment of cancer
EA200901062A1 (en) USING INHIBITORS OF SOLUBLE EPOXYDHYDROLASE FOR THE PREVENTION AND TREATMENT OF METABOLIC SYNDROME AND RELEVANT DISORDERS
NZ622710A (en) Neuroendocrine tumor treatment using mtor inhibitors
WO2008033368A3 (en) Boroproline compound and cytokine combination therapy
EA200870603A1 (en) TREATMENT OF TUMORS IN PEDIATRIC PATIENTS WITH ANTAGONISTS OF THE EPIDERMAL GROWTH RECEPTOR

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 20 NOV 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20151204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2017 BY CPA GLOBAL

Effective date: 20161021

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2018 BY CPA GLOBAL

Effective date: 20171019

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2019 BY CPA GLOBAL

Effective date: 20181018

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2020 BY CPA GLOBAL

Effective date: 20191017

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2021 BY CPA GLOBAL

Effective date: 20201022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2022 BY CPA GLOBAL

Effective date: 20211022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2023 BY CPA GLOBAL

Effective date: 20221020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 NOV 2024 BY CPA GLOBAL

Effective date: 20231019